Date: 2018-01-04
Type of information: Series D financing round
Company: Enterome Bioscience (France)
Investors: BMS (USA - NY) Principia SGR (Italy) Health For Life Capital (Seventure) (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) Omnes Capital (France)
Amount: €32 million ($38.5 million)
Funding type: series D financing round
Planned used:
- The proceeds of the fundraising will be used primarily to progress two proof-of concept clinical trials of Enterome’s lead development programs, a Phase 2 study of the company’s oral FimH blocker EB8018 for the treatment of Crohn’s disease, and a Phase 1b study of EO2315, a novel immuno-oncology candidate, in patients with aggressive brain cancer (glioblastoma multiforme).
- In addition, Enterome will pursue the development of the next generation of its proprietary metagenomics drug discovery platform, reinforcing its leadership in the discovery and development of new therapeutic leads and targets for microbiome-associated diseases and expanding the reach of its technology platforms.
- EB8018 is a novel, first-in-class oral small molecule that is gut-restricted and minimally absorbed into the bloodstream. It represents a non-biologic, non-steroidal, non-immunomodulatory approach for the treatment of Crohn’s Disease. It inhibits FimH-mediated adhesion of some pro-inflammatory bacteria invading the microbiome of Crohn’s patients, such as Adherent Invasive Escherichia coli and Klebsiella, to receptors in the gut wall, thereby reducing the production of inflammatory cytokines including TNF. EB8018 successfully completed a Phase 1 trial in 2017, demonstrating safety and minimal blood absorption.
- EO2315 is the lead candidate originating from Enterome’s technology platform, which is being applied to discover novel bacterial antigens that display similarities with cancer antigens. Such bacterial antigens have been shown to trigger a robust immune response against host antigens specifically expressed in tumors in animal models, thus providing innovative solutions to making cancer cells the target of the adaptive immune system. Enterome has already demonstrated that EO2315 generates a strong immune response against an undisclosed tumor target, resulting in potent tumor cell-killing ex vivo and controlled tumor growth in vivo when combined with a checkpoint inhibitor.
Others:
- • On January 4, 2018, Enterome announced that it has raised €32 million in a Series D financing. All current Enterome investors – Seventure, Health for Life Capital, LundbeckFonden Ventures, Omnes Capital and Nestlé Health Science – participated in the round, alongside new venture investor Principia SGR and strategic investor BMS.
Therapeutic area: Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology
Is general: Yes
